Fig. 3.

Immune features in tumors for B16F10 xenograft mouse model with SB-3CT treatment. a Fluorescence expression and b quantification of CD8⁺ T cells. c Heatmap of Z-score normalized percentage of immune cell populations (d–h) in TILs for B16F10 tumor-bearing mice treated with anti-PD-1 and SB-3CT in combination or alone. d–h In the implanted B16F10 tumors from mice treated with or without SB-3CT and PD-1 blockade, fluorescence-activated cell sorting (FACS) was used to measure d CD8⁺ in CD3⁺ T cells, e CD8⁺ IFNγ⁺ in CD8⁺ T cells, f CD8⁺ GZMB⁺ in CD8⁺ T cells, g Gr-1⁺ CD11b⁺ MDSCs in CD45⁺ cells, and h CD25⁺ FOXP3⁺ Treg in CD4⁺ cells. i Fluorescence expression and j quantification of PD-L1 in B16F10 tumor-bearing wild-type C57/BL6 mice treated with isotype, SB-3CT, anti-PD-1, or combination strategy. Sample size is 5 in each cohort. Scale bars, 50 μm. Results are mean ± s.d. ns, p > 0.05,*p < 0.05, **p < 0.01, and ***p < 0.001, as determined by one-way ANOVA and Dunnett’s multiple comparison test